期刊文献+

雷那度胺治疗骨髓增生异常综合征效果观察

下载PDF
导出
摘要 骨髓增生异常综合征是比较常见的一种血液系统疾病,主要是指造血干细胞增殖分化异常而诱发的一种恶性肿瘤,临床以骨髓细胞异常、全血细胞减少等为主要表现,具有并发症多、风险高等特点,在60岁老年人中具有较高的发病率,严重危害患者的身体健康和生命安全[1]。当前临床治疗骨髓增生异常综合征有多种药物,包括环孢素A、地西他滨以及雷那度胺等,其疗效也存在着一定的差别。因此,本研究对雷那度胺在骨髓增生异常综合征治疗中的临床价值进行探讨,现报道如下。
作者 曾小春
出处 《中国现代医药杂志》 2017年第2期49-50,共2页 Modern Medicine Journal of China
  • 相关文献

参考文献4

二级参考文献38

  • 1ChesonBD,BennettJM,KopeckyKJ,周学慧,肖志坚.国际工作组关于急性髓系白血病治疗试验的诊断、疗效标准的标准化、治疗结局和报告标准的修订建议[J].白血病.淋巴瘤,2004,13(4):246-250. 被引量:31
  • 2Greenberg P, Cox C, LeBeau M M, et al. Znternational scoring system for evaluating prognosis in myelodysplastic syndroms[J]. Blood,1997, 89(6) :2079 -2088.
  • 3Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-close cytosine arabino- side and aclarubicin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia, 1995,9 (1): 10-14.
  • 4Saito K, Nakamaura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubcin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with replapsed or primary resistant acute myelogenous leukemia and previously untreated elderly patients with AML, secondary AML, and refractory anima with excess blastsin transformation[J]. . Int J Hematol,2000 ,71(3):238-244.
  • 5Bai A, Kojima H, Hori M, et,al. Priming with G-CSF effectively enhances low dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells[J]. Exp Hematol , 1999,27 (2) : 259-265.
  • 6Nakamura Y, Arai Y, Gunji H, et al. WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodys- plastic syndrome successfully treated with CAG regimen[J]. Rinsho Ketsueki,2002,43(10) :960-962.
  • 7Haase D,Germing U,Schanz J,et al.New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:evidence from a core dataset of 2124 patients[J].Blood,2007;110(13):4385-95.
  • 8Nimer SD.Myelodysplastic syndromes[J].Blood,2008;111:4841-51.
  • 9Ebert BL,Galili N,Tamayo P,et al.An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome[J].PLoS Med,2008;5(2):312-22.
  • 10Ades L,Boehrer S,Prebet T,et al.Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion:results of a phase 2 study[J].Blood,2009;113(17):3947-52.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部